• In December 2023, Ajinomoto Co., Inc. acquired shares of All Forge Biologics Holdings, LLC to boost its biologics manufacturing and development capabilities, aiming to accelerate innovation and growth in Japan.

• In June 2023, FUJIFILM Corporation opened a new commercial office in Tokyo to strengthen sales and customer support for its contract development and manufacturing services, targeting Asia-based pharmaceutical and biotechnology companies.

In this report, the Vaccine Contract Manufacturing Market has been segmented by Vaccine Type, Workflow, Type, End Use, and Geography.

Vaccine Contract Manufacturing Market, Segmentation by Vaccine Type

The Vaccine Contract Manufacturing Market has been segmented by Vaccine Type into Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccines, Toxoid Vaccines, and DNA Vaccines.

Attenuated Vaccine

Attenuated vaccines make up about 28% of the vaccine contract manufacturing market. These vaccines, which utilize weakened live pathogens, require highly controlled biomanufacturing environments and are often outsourced to CMOs with advanced biosafety infrastructure and large-scale capacity.

Inactivated Vaccine

Inactivated vaccines comprise nearly 24% of the market. Their production involves the killing of pathogens while preserving antigenicity, making them safe and effective. CMOs are frequently contracted to manage their bulk production and formulation.

Subunit Vaccines

Subunit vaccines represent about 20% of the market. These vaccines use isolated proteins or antigens rather than whole pathogens and require highly technical production methods, pushing manufacturers to rely on recombinant technology experts within the contract manufacturing space.

Toxoid Vaccines

Toxoid vaccines account for nearly 15% of the market. Designed to protect against toxin-mediated infections like tetanus, they demand specialized bacterial processing and purification techniques that are commonly managed by experienced CMOs.

DNA Vaccines

DNA vaccines hold an estimated 13% share. Their growing popularity stems from advantages such as rapid development timelines, room-temperature stability, and scalable production, leading to increased reliance on CMOs with plasmid DNA manufacturing capabilities.

Vaccine Contract Manufacturing Market, Segmentation by Workflow

The Vaccine Contract Manufacturing Market has been segmented by Workflow into Downstream [Fill & Finish Operations, Analytical & QC Studies, and Packaging], and Upstream [Mammalian Expression Systems, Bacterial Expression Systems, Yeast Expression Systems, Baculovirus/Insect Expression Systems, and Others]

Downstream

Downstream processes include fill & finish operations, analytical & QC studies, and packaging. These steps are vital for ensuring product safety and regulatory compliance. Fill & finish alone contributes nearly 40% to the downstream segment due to its complexity and critical role.

Upstream

Upstream operations begin with various expression systems used in vaccine development. Mammalian expression systems hold about 35% market share owing to their efficiency in producing complex proteins. Bacterial expression systems contribute approximately 25% due to cost-effectiveness, while yeast systems account for 15%. Baculovirus/insect systems and others jointly make up the remaining 25%, particularly used for specialized vaccines.

Vaccine Contract Manufacturing Market, Segmentation by Type

The Vaccine Contract Manufacturing Market has been segmented by Type into Viral, Bacterial, and Others.

Viral

Viral vaccines lead the vaccine contract manufacturing market with a dominant share of around 65%. This category includes high-demand vaccines such as those for COVID-19, hepatitis, and seasonal influenza. Contract manufacturers are essential partners in scaling up production and ensuring cold chain logistics and compliance with standards.

Bacterial

Bacterial vaccine manufacturing holds approximately 28% of the market. Vaccines for whooping cough, cholera, and meningitis are typically produced through high-volume fermentation and purification techniques, tasks often outsourced to CMOs with advanced bio-processing capabilities.

Others

The others segment comprises around 7% of the market and includes experimental and emerging vaccine types targeting parasites, fungi, and combination antigens. These require customized development approaches, often handled by niche CMOs that specialize in complex vaccine platforms.

Vaccine Contract Manufacturing Market, Segmentation by End Use

The Vaccine Contract Manufacturing Market has been segmented by End Use into Biopharmaceutical Companies and Research Academies & Government Institutes.

Biopharmaceutical Companies

Biopharmaceutical companies dominate the end-use segment with a market share of approximately 76%. These firms increasingly partner with contract manufacturers to handle bulk vaccine production, technology transfer, and GMP compliance, ensuring faster commercialization of vaccines across global markets.

Research Academies & Government Institutes

Research academies and government bodies represent about 24% of the market. These institutions engage CMOs for the development of investigational vaccines, early-phase research, and public immunization strategies, particularly during global health emergencies.

Vaccine Contract Manufacturing Market, Segmentation by Geography

In this report, the Vaccine Contract Manufacturing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Vaccine Contract Manufacturing Market Share (%), by Geographical Region

North America

North America leads the vaccine contract manufacturing market with a share of close to 40%. This dominance is attributed to its cutting-edge facilities, extensive vaccine R&D activities, and long-standing partnerships between CMOs and major pharmaceutical players.

Europe

Europe captures around 26% of the global market. The region is known for its strong regulatory framework, skilled workforce, and pharmaceutical innovation, making it a key player in outsourced vaccine production.

Asia Pacific

Asia Pacific holds roughly 22% of the market and is rapidly emerging as a vaccine manufacturing hub. Competitive labor costs, government incentives, and increased vaccine demand contribute to the rise of CMOs across the region.

Middle East and Africa

Middle East and Africa account for about 7% of the market. While the region is still developing its infrastructure, initiatives led by WHO, GAVI, and local governments are expanding the reach of vaccine production capabilities.

Latin America

Latin America comprises nearly 5% of the market. The region is seeing gradual growth through regional production efforts, partnerships with CMOs, and improved public health strategies to ensure vaccine availability.

This report provides an in depth analysis of various factors that impact the dynamics of Vaccine Contract Manufacturing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Growing Vaccine Demand Globally
• Technological Advancements in Manufacturing
• Increasing Government Initiatives

• Rise in Infectious Diseases - Rise in infectious diseases is a major driver of growth in the vaccine contract manufacturing market. The increasing incidence of infectious outbreaks such as COVID-19, influenza, HPV, and emerging zoonotic diseases has heightened global demand for rapid and scalable vaccine production. Governments and health organizations are seeking to strengthen preparedness by ensuring faster vaccine development and deployment, driving the need for specialized contract manufacturing organizations (CMOs) with advanced capabilities.

  CMOs offer critical support in scaling production, meeting regulatory standards, and accelerating time-to-market, especially during public health emergencies. As new variants and novel pathogens continue to emerge, the demand for flexible, high-capacity manufacturing solutions will remain strong, positioning vaccine contract manufacturing as a vital component of global immunization strategies.

Restraints

• Stringent Regulatory Requirements
• Limited Skilled Workforce

• Supply Chain Disruptions - Supply chain disruptions serve as a significant restraint in the vaccine contract manufacturing market. The production of vaccines depends on a complex, global supply chain involving raw materials, specialized equipment, cold-chain logistics, and stringent quality control protocols. Disruptions due to geopolitical tensions, pandemics, trade restrictions, or shortages of critical components can cause delays in manufacturing timelines and hinder distribution, negatively impacting market performance.

  These vulnerabilities highlight the importance of a resilient and diversified supply network, but building such infrastructure requires time, investment, and cross-border coordination. For contract manufacturers, maintaining consistent access to high-quality raw materials and logistics support remains a major challenge, particularly during global crises. As a result, supply chain instability can limit scalability, affect contractual obligations, and slow the overall growth of the vaccine contract manufacturing sector.

Opportunities

• Modular, Single-Use & Agile Manufacturing
• Collaborations and Partnerships

• Development of Novel Vaccines - Development of novel vaccines presents a significant opportunity for the vaccine contract manufacturing market. Advances in biotechnology and immunology are driving the creation of innovative vaccines targeting a wide range of diseases, including cancer, HIV, Zika, and other emerging infectious threats. These novel formulations often require specialized expertise and flexible manufacturing capabilities, which contract manufacturers are uniquely positioned to provide.

  As pharmaceutical companies focus on accelerating research pipelines, they are increasingly outsourcing production to CMOs to reduce time-to-market and manage costs. This growing demand for scalable, compliant, and technologically advanced facilities is creating new growth avenues for vaccine contract manufacturers. The rise of mRNA, vector-based, and personalized vaccines further underscores the need for cutting-edge manufacturing partnerships to support rapid and efficient commercialization.

Vaccine Contract Manufacturing Market is witnessing strong competition among contract development and manufacturing organizations (CDMOs), biotechnology firms, and pharmaceutical companies. The market demonstrates robust growth driven by rising vaccine demand, outsourcing trends in biopharmaceutical production, and rapid innovation in biologics manufacturing. Around 65% of the market share is held by major players emphasizing innovation, collaboration, and large-scale production capabilities.

Market Structure and Concentration
The market exhibits moderate concentration, with top CDMOs and biomanufacturers accounting for approximately 60% share through advanced vaccine production facilities and strategic partnerships. Mergers, acquisitions, and technology alliances strengthen expertise in formulation, fill-finish, and cold chain logistics. This structure supports expansion across infectious disease, oncology, and mRNA vaccine platforms worldwide.

Brand and Channel Strategies
Leading manufacturers adopt integrated strategies including end-to-end development support, long-term outsourcing contracts, and collaborations with government and global health organizations. Nearly 50% of total revenue is derived from viral vector and recombinant vaccine manufacturing. Strong brand credibility, regulatory compliance, and collaboration with pharmaceutical developers enhance trust and long-term client relationships.

Innovation Drivers and Technological Advancements
Continuous innovation in bioprocessing, cell culture, and modular facility design drives efficiency and scalability. Around 55% of R&D investment focuses on technological advancements improving yield, process automation, and product stability. Integration of single-use bioreactors, AI-based quality analytics, and digital manufacturing platforms enhances efficiency and ensures faster production turnaround.

Regional Momentum and Expansion
North America dominates the market with approximately 45% share owing to advanced biomanufacturing infrastructure and government vaccine initiatives. Europe exhibits steady expansion through innovation in biotechnological research, while Asia Pacific records rapid growth driven by cost-efficient production and capacity investments. Regional partnerships among CDMOs, vaccine developers, and research institutes strengthen supply networks and technology transfer.

Future Outlook
The future outlook for the Vaccine Contract Manufacturing Market remains highly favorable with continuous growth in global immunization programs and biologics outsourcing. Continued innovation in mRNA platforms, cold chain logistics, and process optimization will redefine vaccine manufacturing standards. Strengthened collaboration among CDMOs, biotech firms, and public health organizations will ensure accessibility, efficiency, and long-term market expansion.

Key players in Vaccine Contract Manufacturing Market include:

• Lonza
• Catalent
• Thermo Fisher Scientific
• Samsung Biologics
• Boehringer Ingelheim BioXcellence
• IDT Biologika
• FUJIFILM Diosynth Biotechnologies
• Merck KGaA
• Cytovance Biologics
• Ajinomoto / Ajinomoto Bio-Pharma Services
• Charles River Laboratories / Cobra Biologics
• PRA Health Sciences / PPD
• ICON plc
• Albany Molecular Research Inc.
• Emergent BioSolutions

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis